Carlos Eugenio

[ESTRO @ESTRO_RT]

How to focal boost in #ProstateCancer radiotherapy: ESTRO clinical practice consensus recommendations.
👉 Read the article in open access in the #GreenJournal: https://t.co/FRWjKEaBT8

#radiotherapy #guidelines #RadiationOncology

[Applied Radiation Oncology @Applied_RadOnc]

Research Article: Personality Mapping and Emotional Intelligence Education in Radiation Oncology

Read it here: https://t.co/6CigKacG2u

This study explored the distribution of personality profiles across professional roles within a radiation oncology department using the True Colors framework as part of an educational initiative.

#RadOnc #RadiationOncology #CancerCare #RadOncEd #MedEd

[Clinical Nuclear Medicine @ClinNuclearMed]

Current Issue: 68Ga-DOTA-IBA Uptake in Meningioma and Liver Metastasis of Breast Cancer https://t.co/u0lClZRGZc

[Applied Radiation Oncology @Applied_RadOnc]

Case Report: Abscopal effect of radiation therapy in monotherapy in a patient with malignant melanoma

Case details 🔗 https://t.co/y4YzQnQBWe

#RadOnc #RadiationOncology #CancerCare #CaseStudy #RadOncEd #MedEd #Melanoma

[ESTRO @ESTRO_RT]

The YAU #ProstateCancer Working Group in collaboration with the ESTRO #Urology Focus Group need your insights on bone health management for patients receiving ADT. Help us map global clinical challenges.
📅 Closes Sept 2026
👉https://t.co/31aNy3wJSY #RadOnc #MedOnc

[Erman Akkus @Erman_Akkus]

💊Cancer pain management
NCCN guideline summary

#cancer #oncology #MedX #pain

[ASTRO @ASTRO_org]

Li et al. write about radiation-induced hypothyroidism in patients with breast cancer after hypofractionated radiotherapy in this new #RedJournal article - results also presented at #ASTRO22! https://t.co/XfiJI9xZJO

[Applied Radiation Oncology @Applied_RadOnc]

A Rare Case of Skull Base Phosphaturic Mesenchymal Tumor

🔗 See all case details here: https://t.co/BdQJIZ6d2K

Phosphaturic mesenchymal tumor (PMT) is a rare type of tumor that presents as a paraneoplastic syndrome causing tumor-induced osteomalacia. So far, close to 500 cases have been reported in the literature, making it a rare entity in clinical practice. The most common sites of PMT involvement are extremities. Here, we report a rare case of PMT involving the skull base.

#RadOnc #RadiationOncology #CancerCare #CaseStudy #RadOncEd #MedEd

[Applied Radiation Oncology @Applied_RadOnc]

Radiation Therapy Shows Promise in Treating Benign Proliferative Diseases of the Extremities

🔗📰 Read the full article: https://t.co/cdnXPvemvZ

#RadOnc #RadOncNews #RadiationOncology #CancerCare
(Image from @CleClinicMD

[ASTRO @ASTRO_org]

New in #practicalRO: A Primer on Treatment Planning Aspects for Temporally Modulated Pulsed Radiation Therapy. https://t.co/RRM6HMMOM4

[Applied Radiation Oncology @Applied_RadOnc]

Case Study: Craniospinal Irradiation for Leptomeningeal Disease in Recurrent Breast Cancer

🔗 Full details here: https://t.co/YM50eJikKs

LMD is an uncommon complication of breast cancer associated with a poor prognosis. We highlight the challenges of diagnosis and the importance of obtaining an MRI of the entire neuroaxis, cytologic analysis, and correlation with neurological assessment.

#RadOnc #RadiationOncology #CancerCare #CaseStudy #RadOncEd #MedEd

[Advances, an ASTRO Journal @Advances_ASTRO]

Can 3 Gy help osteoarthritis pain?

In this US retrospective series, LDRT 0.5 Gy x 6 improved mean Numeric Rating Scale pain scores from 7.3 to 2.6 at ~12 weeks, with 79% achieving a clinically meaningful ≥2-point reduction.

Low burden.

Noninvasive.

Interesting signal for selected patients with persistent OA pain.

#OncTwitter #RadOnc

[Luis Moreno Sánchez @radioncoluis]

Patient selection for APBI after breast-conserving surgery: Updated evidence-based recommendations of the GEC-ESTRO Breast Cancer Working Group.

https://t.co/gmvyiWkzpH

[Luis Moreno Sánchez @radioncoluis]

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026

https://t.co/GExqGarHFh

[PDBrown @PDBrownOnc]

LDRT for Greater Trochanteric Pain Syndrome (GTPS) and/or Hip OA
Response rate 64% GTPS, 58% Hip OA
↓↓response GTPS symptoms > 1yr, pain flare, hip prosthesis
↓↓response Hip OA BMI > 25, pain flare, >70yo
https://t.co/vz9a6ZFNx1

[ASTRO @ASTRO_org]

Don't miss the hands-on eContouring sessions at the ASTRO Annual Meeting that provide crucial contouring education and experience. Check out the schedule and details here: https://t.co/K5meo8hApk #ASTRO19 #RadOnc

[PDBrown @PDBrownOnc]

Does distance from isocenter impact LC for Single Iso MutliTarget SRS with Zero margin?
NO, according to this UAB brain met study
1 Yr LC 95%
https://t.co/gVHtP4CGpv

[PDBrown @PDBrownOnc]

ASCO2026: Asymptomatic brain met EGFR/ALK NSCLC any benefit upfront cranial RT on this Randomized trial?
- Upfront RT ↑↑ brain control, no benefit PFS, OS
- Selection criteria high risk (e.g. larger size) for upfront RT is key
https://t.co/1CM31nbxeL

[Mukund Iyengar @mukundiyngr]

ASCO this year has 5,000+ abstracts.

But maybe 24 will actually change practice. This is that map.

(ERRATA: this plot fixes an error on VICTORIA which reflected incorrect data, thnx @Dr_RShatsky)

Map spans 12 disease areas, 24 critical readouts, 5 plenaries & 2 confirmed misses already on the board.

Few things jump out immediately:
▫️Pancreatic cancer gets the headline.
Daraxonrasib: 13.2 vs 6.7 months.
▫️Sarcoma gets a plenary because public science funded what pharma would not.
▫️Lung cancer remains the most crowded battlefield in oncology:
RET adjuvant, bispecific OS, post-osimertinib, next-gen EGFR.

By next week, some of these cells will become new standards of care.

This is your cheat sheet to keep score in real time.

- - - - -
Sources: @asco @OncLive @CancerNetwrk via @Jori_health
- - - - -

[ASTRO @ASTRO_org]

📍 Join us in Boston or virtually for ASTRO 2026, September 26–30!
Registration and housing are now open: book early for the best hotel rates and selection.

⏰Register by June 25, 2026, to save with Early-bird rates. We can’t wait to see you at ASTRO’s 68th Annual Meeting! #ASTRO26

Secure your spot today: https://t.co/c0yQOrBccR